Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SA001 in Primary Sjögren's Syndrome
NCT05269810Phase 2Completed
- Sponsor
- Samjin Pharmaceutical Co., Ltd.
- Start
- May 2020
- Primary completion
- Feb 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rebamipide mofetil (4 arms), sponsored by Samjin Pharmaceutical Co., Ltd. Primary endpoints: Tear Break-Up Time at Day 56, Ocular Staining Score at Day 56 and 6 more. Started May 2020; status: completed.
02
Drugs
rebamipide mofetil
Beyond the preview
Go deeper on NCT05269810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05269810.